Conjugating antimalarial drugs primaquine and chloroquine to the cell-penetrating peptide TP10 increased antiplasmodial activity but caused severe hemolysis, demonstrating that cell-penetrating peptides are unsuitable carriers for aminoquinoline antimalarials.
Enhanced potency but hemolytic — unsuitable for clinical useDespite increased antiplasmodial activity, the CPP-antimalarial conjugates destroyed red blood cells, demonstrating that cell-penetrating peptides are not universally safe carriers for all drug types
What the researchers found
Chloroquine-TP10 conjugates showed higher antiplasmodial activity than the parent TP10 peptide alone. However, both chloroquine-TP10 and primaquine-TP10 conjugates exhibited strong hemolytic activity — they bound to and destroyed red blood cell membranes, as demonstrated by fluorescence microscopy and flow cytometry.
This is a critical negative finding: despite cell-penetrating peptides being widely reported as safe and effective carriers for diverse cargoes (from small drugs to large biomolecules), coupling them to aminoquinoline antimalarials specifically produces unacceptable hemolysis. The authors conclude that cell-penetrating peptides are unsuitable for safe intracellular delivery of this drug class and urge researchers to systematically assess hemolytic effects in all peptide-drug conjugate development.
Why it matters
Malaria kills over 600,000 people annually, and drug resistance is a growing threat. Cell-penetrating peptides were seen as a promising strategy to enhance drug delivery into infected red blood cells. This study provides a critical safety warning that could prevent wasted research effort and, more importantly, prevent potential harm if such conjugates were advanced without proper hemolysis testing. It also highlights a broader principle: peptide-drug conjugates can have emergent toxicities that neither component shows alone.
How the study worked
Multiple chloroquine-TP10 and primaquine-TP10 conjugates were synthesized and tested for antiplasmodial activity against P. falciparum. Hemolytic activity was assessed using red blood cell lysis assays. Fluorescence microscopy and flow cytometry were used to visualize and quantify conjugate binding to erythrocyte membranes. A panel of different cell-penetrating peptides was tested to determine if the effect was specific to TP10.
What this study cannot tell us
The study focused on aminoquinoline antimalarials (chloroquine, primaquine) specifically, so the hemolysis finding may not apply to other drug classes conjugated to CPPs. The range of cell-penetrating peptides tested was limited. In vivo antimalarial activity and hemolysis were not assessed — the findings are based on in vitro assays. The mechanism of hemolysis (whether driven by the peptide, the drug, or the conjugation chemistry) was not fully dissected.
How to read the evidence
This is a preclinical in vitro study with multiple validated assays (antiplasmodial activity, hemolysis, fluorescence microscopy, flow cytometry). The negative finding is robust and well-supported, making this a valuable cautionary contribution to the CPP field despite being an unfavorable result for drug development.
When this study was published
Published in 2019, this study remains highly relevant as cell-penetrating peptides continue to be widely explored for drug delivery across therapeutic areas.
The bigger picture
Cell-penetrating peptides (CPPs) have been celebrated as versatile delivery vehicles for over two decades, successfully transporting nucleic acids, proteins, imaging agents, and small molecules across cell membranes. This study provides an important counterexample — not all peptide-drug combinations are safe. For malaria specifically, the problem is fundamental: aminoquinoline drugs target parasites inside red blood cells, but the CPP carrier destroys the very cells it needs to penetrate. This highlights the need for systematic toxicity assessment in the CPP field and may redirect malaria peptide research toward alternative delivery strategies like nanoparticles or liposomes.
Questions still open
- Could alternative delivery strategies (nanoparticles, liposomes, prodrug approaches) deliver aminoquinolines more effectively without hemolysis?
- Is the hemolysis specific to aminoquinoline-CPP conjugates, or should all CPP-drug conjugates be systematically screened for hemolytic activity?
- Could chemical modifications to the CPP-drug linker reduce erythrocyte membrane binding while maintaining cell penetration of infected cells?
Common questions
Why is hemolysis such a big problem for antimalarial drugs?
Does this mean cell-penetrating peptides are unsafe in general?
Read the original research
Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates.
Molecules (Basel, Switzerland), 24(24)
Citation
Aguiar, Luísa; Biosca, Arnau; Lantero, Elena; Gut, Jiri; Vale, Nuno; Rosenthal, Philip J; Nogueira, Fátima; Andreu, David; Fernàndez-Busquets, Xavier; Gomes, Paula. (2019). Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates.. Molecules (Basel, Switzerland), 24(24). https://doi.org/10.3390/molecules24244559